New combo attack on rectal cancer before surgery
NCT ID NCT07381400
Summary
This study is testing if adding an immunotherapy drug (Serplulimab) to standard chemotherapy before surgery works better for people with a certain type of locally advanced rectal cancer. It will involve 128 patients who have not yet had treatment. Half will get the standard chemo, and half will get the chemo plus immunotherapy, to see which approach leads to better results and fewer cancer cells remaining at surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.